|
The laboratory has established a portfolio of approximately 15 patents on new drug candidates and fluorescence technologies. Several groups of patents have been licensed on an exclusive basis.
We are currently seeking industrial partners / licensees in the following areas:
- CFTR inhibitors for therapy of polycystic kidney disease
- Calcium-activated chloride channel inhibitors for diarrhea / mucus secretion
- Urea transport inhibitors as diuretics in hypertension and heart failure
- Aquaporin screening methodology and candidate inhibitors
- Potassium-sensing fluorescent dyes
For further information, contact Dr. Eileen Lee, U.C.S.F. Office of Technology Management: Eileen.Lee@ucsf.edu
| References |
|
Yang, B., N.D. Sonawane, D. Zhao, S. Somlo and A.S. Verkman (2008). Small-molecule CFTR inhibitors slow cyst growth in polycystic kidney disease. J. Am. Soc. Nephrol. 19:1300-1310. |
|
Sonawane, N. and A.S. Verkman (2008). Thiazolidinone CFTR inhibitors with improved water solubility identified by structure-activity analysis. Bioorg. Med. Chem. In press. |
|
De La Fuente, R., W. Namkung, A. Mills and A.S. Verkman (2008). Small-molecule screen identifies inhibitors of a human intestinal calcium-activated chloride channel. Mol. Pharmacol. 73:758-768. |
|
Namkung, W., P. Padmawar, A.D. Mills and A.S. Verkman (2008). Fluorescence cell-based screen for K+ channels and transporters using an extracellular triazacryptand-based K+ indicator. J. Am. Chem. Soc. 130:7794-7795. |
|
Levin, M.H., R. de la Fuente and A.S. Verkman (2007). Urearetics: a small molecule screen yields nanomolar potency inhibitors of urea transporter UT-B. Faseb J. 21:551-563. |
|
Padmawar, P., X. Yao, O. Bloch, G.T. Manley and A.S. Verkman (2005). K+ waves in brain cortex visualized using a long-wavelength K+-sensing fluorescent indicator. Nature Meth. 2:825-827. |
|
